GlaxoSmithKline and collaborator Vir Biotechnology aim to widen the scope of the trial for their experimental antibody as a treatment for COVID-19 after no safety concerns were raised in the first 20 volunteers. The expanded trial will have half of the 1,300 participants randomly assigned to receive a placebo, with interim trial results expected to become available possibly by year's end and complete efficacy results slated to be released by within the first quarter of next year.
GSK, Vir to expand trial for COVID-19 antibody treatment
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.